GlobalData reports that the travel & tourism sector experienced a notable decline in deal activity in the first half of 2025.

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

Shumita Sharma Deveshwar, chief India economist at GlobalData.TSLombard, discusses the implications of a 25% tariff rate on ...

AI in the healthcare space has outpaced the rate of regulation, and without an update, HIPAA risks stifling innovation.

Stryker’s financials revealed total sales of $3.7bn in its medical surgery and neurotechnology business unit, up 17.3% on Q2 ...

Anavex's blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.

In an update on the global apparel sector, GlobalData forecasted Adidas will “remain one of the biggest winners within the ...

Following its purchase Poppi, PepsiCo's prebiotic cola push shows it sees prebiotics being a category that’s here to stay.

Global deal activity witnessed a 1.7 per cent year-on-year decline during the first half (H1) of 2025, reflecting a mixed global sentiment amid ongoing economic uncertainties, according to GlobalData.

New Zealand’s mobile services revenue is poised to grow at a modest compound annual growth rate (CAGR) of 1.5 per cent from ...

The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...

South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...